An adverse events potential costs analysis based on Drug Programs in Poland. Dermatology focus

• Authors: Monika Szkultecka-Debek , Mariola Drozd , Nina Kiepurska , Agnieszka Janowska , Piotr Paprzycki , Beata Paluchowska
• Languages of publication: EN

Abstracts

EN

The aim of the project, carried out within the Polish Society for Pharmacoeconomics (PTFE), was to estimate the potential costs of treatment of the side effects which (theoretically) may occur as a result of treatments for the selected diseases. This paper deals solely with dermatology related events. Herein, several Drug Programs financed by the National Health Fund in Poland, in 2012, were analyzed. The adverse events were selected based on the Summary of Product Characteristics of the chosen products. We focused the project on those potential adverse events which were defined in SPC as frequent and very frequent. The results are presented according to their therapeutic areas, and in this paper, the focus is upon that which is related to dermatology. The events described as ‘very common’ had an incidence of ≥ 1/10, and that which is ‘common’ - ≥ 1/100, <1 /10. In order to identify the resources used, we, with the engagement of clinical experts, performed a survey. In our work, we employed only the total direct costs incurred by the public payer, based on valid individual cost data in February 2014. Moreover, we calculated the total spending from the public payer’s perspective, as well as the patient’s perspective, and the percentage of each component of the total cost in detail. The paper, thus, informs the reader of the estimated costs of treatment of side effects related to the dermatologic symptoms and reactions. Based on our work, we can state that the treatment of skin adverse drug reactions generates a significant cost - one incurred by both the public payer and the patient.

Keywords

EN

the cost treatment; adverse events; dermatology

• Publisher: De Gruyter Open
• Journal: Current Issues in Pharmacy and Medical Sciences
• Year: 2014
• Volume: 27
• Issue: 3
• Pages: 183-186

Dates

published

1 - 9 - 2014

accepted

3 - 11 - 2014

online

3 - 3 - 2015

received

9 - 10 - 2014

Contributors

author

Monika Szkultecka-Debek

• Dermatology, Military Institute of Medicine, 128 Szaserow, 04-141 Warsaw, Poland

author

Mariola Drozd

• Department of Applied Pharmacy, Medical University of Lublin, Poland

author

Nina Kiepurska

• Dermatology, Military Institute of Medicine, 128 Szaserow, 04-141 Warsaw, Poland

author

Agnieszka Janowska

• Department of Functional Research, Institute of Rural Health in Lublin, Poland

author

Piotr Paprzycki

• Department of Functional Research, Institute of Rural Health in Lublin, Poland

author

Beata Paluchowska

• Dermatology, Military Institute of Medicine, 128 Szaserow, 04-141 Warsaw, Poland

References

• 1. Bates D.W. et al.: The cost of adverse drug events in hospitalized patients. JAMA, 277, 4, 1997.
• 2. Borovicka J.H. et al.: Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Arch Dermatol., 147, 12, 2011. doi: 10.1001/archdermatol.2011.719.[Crossref]
• 3. Classen D.C. et al: Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA, 277, 4, 1997.
• 4. Dubey A.K. et al.: Dermatological adverse drug reactions due to systemic medications. A review of literature; Journal of Pakistan Association of Dermatologists, 16, 2006.
• 5. Koelblinger P. et al.: Skin manifestations of outpatient adverse drug events in the United States: a national analysis. J Cutan Med Surg., 17, 4, 2013.[WoS][Crossref]
• 6. Pliki parametryzujące. Online: http://jgp.uhc.com.pl/doc/index. html, Access: 2014.06.20
• 7. Rozporządzenie Ministra Zdrowia z 2 kwietnia 2012 r. w sprawie minimalnych wymagań, jakie muszą spełniać analizy uwzględnione we wnioskach o objęcie refundacją i ustalenie urzędowej ceny zbytu oraz o podwyższenie urzędowej ceny zbytu leku, środka spożywczego specjalnego przeznaczenia żywieniowego, wyrobu medycznego, które nie mają odpowiednika refundowanego w danym wskazaniu. Dz. U. 2012, poz. 388
• 8. Stausberg J., Hasford J.: Drug-related admissions and hospitalacquired adverse drug events in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data. Health Services Research, 11, 2011.
• 9. Szkultecka-Debek M. et al.: Adverse events (AE) cost assessed in Poland based on existing Drug programs - methodology of the project. Curr. Issues Pharm. Med. Sci., 26, 4, 2013.
• 10. Ustawa z dn. 12 maja 2011 roku. O refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych. Dz. U. 2011 nr 122 poz. 696 z późn. zm.;
• 11. Wiśniewska N. et al.: The direct costs of drug-induced skin reactions in Poland. Value in Health, 16, 7, 2013.
• 12. Załącznik do Obwieszczenia Ministra Zdrowia z dnia 23 czerwca 2014 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na dzień 1 lipca 2014 r. Online: http:// www.mz.gov.pl/leki/refundacja/lista-lekow-refundowanychobwieszczenia- ministra-zdrowia. Access: 2014.07.01

Identifiers

DOI

10.1515/cipms-2015-0012